Abbott India growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+8.1%+9.0%
EBITDA+11.7%+16.2%
Net Income+9.7%+17.8%
Total Assets+9.9%+12.6%
Total Equity+12.8%+14.4%
Free Cash Flow+30.4%+13.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ABBOTINDIA₹26,275.00

Abbott India Ltd.

· Pharma & Health
₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+8.1+9.0
EBITDA+11.7+16.2
Net Income+9.7+17.8
Total Assets+9.9+12.6
Total Equity+12.8+14.4
Free Cash Flow+30.4+13.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.